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Abstract
Background: Granulocyte-macrophage colony-stimulating factor (GM-CSF) has shown promising
results as a cytokine adjuvant for antiviral vaccines and in various models of tumor gene therapy.
To explore whether the targeting of antigens to GM-CSF receptors on antigen-presenting cells
enhances antigen-specific CD8 T-cell responses, fusion proteins of GM-CSF and ovalbumin (OVA)
were expressed by DNA and adenoviral vector vaccines. In addition, bicistronic vectors allowing
independent expression of the antigen and the cytokine were tested in parallel.
Results: In vitro, the GM-CSF ovalbumin fusion protein (GM-OVA) led to the better stimulation of
OVA-specific CD8+ T cells by antigen-presenting cells than OVA and GM-CSF given as two
separate proteins. However, prime-boost immunizations of mice with DNA and adenoviral vector
vaccines encoding GM-OVA suppressed CD8+ T-cell responses to OVA. OVA-specific IgG2a
antibody levels were also reduced, while the IgG1 antibody response was enhanced. Suppression
of CD8+ T cell responses by GM-OVA vaccines was associated with the induction of neutralizing
antibodies to GM-CSF. In contrast, the coexpression of GM-CSF and antigens in DNA prime
adenoviral boost immunizations led to a striking expansion of polyfunctional OVA-specific CD8+
T cells without the induction of autoantibodies.
Conclusion: The induction of autoantibodies suggests a general note of caution regarding the use
of highly immunogenic viral vector vaccines encoding fusion proteins between antigens and host
proteins. In contrast, the expansion of polyfunctional OVA-specific CD8+ T cells after
immunizations with bicistronic vectors further support a potential application of GM-CSF as an
adjuvant for heterologous prime-boost regimens with genetic vaccines. Since DNA prime
adenoviral vector boost regimenes are presently considered as one of the most efficient ways to
induce CD8+ T cell responses in mice, non-human primates and humans, further enhancement of
this response by GM-CSF is a striking observation.
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Background
The induction of strong CTL responses by prophylactic
and therapeutic vaccines is considered necessary for the
control of chronic viral infections and cancer [1-3].
Genetic vaccines seem to be promising tools, since the
expression of antigen by the vaccinee leads to improved
MHC-I restricted cellular immune responses. DNA vac-
cines have been shown to elicit CTL, T helper and anti-
body responses in a variety of animal models [4-8].
However, DNA vaccines alone stimulated only weak T-cell
responses in monkeys [9] and humans [10]. To enhance
antigen expression levels, various viral vector vaccines
have been explored. For example, antigens expressing
viral vectors based on poxviruses or adenoviruses were
shown to be potent inducers of antigen-specific immune
responses in SIV/HIV vaccine studies [9,11]. In addition
to increased expression levels, the triggering of innate
immune responses by the viral vector particles also seems
to contribute to the immunogenicity of viral vector vac-
cines. However, in contrast to DNA vaccines, repeated
immunizations with the same viral vector vaccine appear
to be limited by immune responses to the viral vector par-
ticles [12,13]. Thus, DNA prime viral vector boost regi-
mens are considered to be one of the most promising
strategies to induce long-lasting CTL responses in humans
[9,14,15].
In addition to prime-boost regimens, a variety of adju-
vants including immunomodulatory cytokines such as
GM-CSF [16-22] were explored to improve the efficacy of
DNA vaccines.
GM-CSF expression plasmids were co-injected with plas-
mids encoding vaccine antigens to examine the adjuvant
activity in mouse models for HIV-1 [17-19], Hepatitis C
virus [20,21] and HSV-2 [22] infection. Coexpression of
GM-CSF enhanced antigen-specific T-cell proliferation
and humoral immune responses, but had little effect on
CTL responses. Over-expression of GM-CSF at the injec-
tion site led to the increased recruitment of macrophages
and dendritic cells (DCs) [23,24] and influenced the acti-
vation status of antigen-presenting cells (APCs) [25]. The
temporal and spatial co-expression of antigens and GM-
CSF seems to be critical for optimal T-cell priming [26]. In
addition, the fusion proteins of antigens and GM-CSF
[27] and DNA vaccines encoding such fusion proteins
[28,29] were shown to improve antigen-specific antibody
responses and cancer immunotherapy. The covalent link-
age of the antigen and GM-CSF might allow the targeting
of APCs expressing GM-CSF receptors, such as DCs. This
could improve antigen uptake and presentation and thus
also enhance CD8 T cell responses, similar to targeting
strategies based on the macrophage mannose receptor or
the DEC205 receptor [30,31]. Therefore, we compared the
antigen-specific CD8 T-cell responses induced by DNA
vaccines encoding GM-CSF ovalbumin fusion proteins
(GM-OVA) with those raised by DNA vaccines coexpress-
ing GM-CSF and ovalbumin (OVA) as two unlinked pro-
teins. Since the antigen expression levels of, and the
innate response to, DNA and viral vector vaccines differ
considerably, the effect of GM-CSF was determined in
DNA immunizations and DNA prime adenoviral vector
boost regimens. Surprisingly, immunization with genetic
vaccines encoding the GM-CSF ovalbumin fusion protein
suppressed CD8+ T cell responses, while coexpression of
GM-CSF was found to be a potent stimulator of antigen-
specific CD8+ T cell responses. Induction of autoantibod-
ies neutralizing GM-CSF by genetic vaccines encoding the
fusion-protein, but not those coexpressing GM-CSF and
OVA, might explain the varying effects observed.
Results
DNA and adenoviral vector vaccines
The expression plasmid encoding the fusion protein of
GM-CSF and ovalbumin (GM-OVA) was generated by
cloning the murine GM-CSF cDNA, a flexible linker, the
OVA cDNA and a HIS6-tag as a single open reading frame
into pcDNA3.1 (Fig. 1A). Three control plasmids express-
ing ovalbumin alone (OVA), ovalbumin fused to the
leader peptide of GM-CSF (ΔGM-OVA), or ovalbumin
fused to the open reading frame of rhesus monkey GM-
CSF (GMrh-OVA), which is biologically inactive in murine
cells, were also constructed. Coexpression of murine GM-
CSF and OVA from the same plasmid was achieved by a
modified bidirectional promoter based on the immediate
early gene of human cytomegalovirus (GM-DP-OVA).
After transient transfection into 293T cells, expression of
the recombinant proteins was detected in cell superna-
tants by Western Blot analysis. The OVA plasmid and the
ΔGM-OVA plasmid expressed a protein of 50 kD, which
corresponds to the size of ovalbumin, whereas both
fusion proteins migrate at a size of about 75 kD (Fig 1B).
The expression levels of the plasmids encoding the fusion
proteins were slightly higher than those obtained with
OVA and ΔGM-OVA, whereas the expression of ovalbu-
min from the GM-DP-OVA plasmid is reduced substan-
tially, probably due to a lower activity of the bidirectional
promoter. GM-DP-OVA lacks the C-terminal tag explain-
ing the slightly lower size of the protein in the Western
blot (Fig. 1B). For further in vitro characterization of GM-
OVA, the protein was purified from transfection superna-
tants via Ni2+-NTA agarose beads. Using a GM-CSF-
dependent cell line, comparable bioactivity was observed
for GM-OVA and control supernatants from a GM-CSF
producer cell line (data not shown). Adenoviral vectors
containing the expression cassettes GM-OVA, GM-DP-
OVA, GMrh-OVA or ΔGM-OVA were constructed using the
pAd-Easy system. Expression of the transgenes and GM-
CSF bioactivity was confirmed for the adenoviral vectors
after infection of 293 cells. The relative expression levelsBMC Immunology 2008, 9:13 http://www.biomedcentral.com/1471-2172/9/13
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of OVA by the different adenoviral vector constructs mir-
rored those observed after transient transfections of the
corresponding plasmid DNAs (data not shown). To com-
pare the expression levels of GM-CSF, serial dilutions of
the supernatants of 293 cells infected with the adenoviral
vectors were tested in a proliferation assay with a GM-CSF-
dependent cell line (Fig 1C.) In contrast to the OVA
expression levels, the bicistronic vector expressed slightly
higher levels of bioactive GM-CSF in comparison to the
vector encoding the GM-OVA fusion protein. The super-
natants of cells infected with adenoviral vectors enoding
GMrh-OVA or ΔGM-OVA did not induce proliferation of
the GM-CSF-dependent murine cell line. Since GMrh-OVA
has GM-CSF activity on human cells (data not shown),
rhesus monkey GM-CSF is not bioactive on murine cells.
Influence of the GM-CSF fusion protein on dendritic cell 
differentiation and antigen presentation
GM-CSF plays a critical role in the differentiation of den-
dritic cells. Bone marrow derived monocytes (BMDM) can
be differentiated into immature DCs by co-culture with
GM-CSF and IL-4. The ability of purified GM-OVA to gen-
erate DCs was therefore compared to recombinant GM-
CSF. Recombinant GM-CSF and GM-OVA were equally
efficient in generating immature DC (low CD80, CD83,
CD86) from BMDMs. To a similar extent, the immature
DCs induced by GM-OVA or recombinant GM-CSF could
be matured by LPS as evidenced by the upregulation of co-
stimulatory molecules (Fig 2A). To test whether the fusion
of GM-CSF to ovalbumin enhances the activation of anti-
gen-specific CD8+ T cells by antigen-presenting cells
(APC), splenocytes from T-cell receptor transgenic OT-I
mice were labeled with CFSE and cultured in the presence
of decreasing concentrations of GM-OVA or ovalbumin
for four days. The proliferation-dependent decrease in
CFSE fluorescence of CD8+ T-cells was analyzed by FACS.
GM-OVA induced proliferation of OT-I cells at 10-fold
lower concentrations than ovalbumin (Fig 2B). The addi-
tion of recombinant GM-CSF to ovalbumin-containing
cultures did not enhance proliferation of OT-I cells (data
not shown), suggesting that the fusion protein enhances
presentation of ovalbumin peptides most likely by GM-
CSF receptor positive APCs.
CD8+ T cell responses after immunization with gene-based 
vaccines encoding the GM-CSF fusion protein
Since the GM-OVA fusion protein maintained GM-CSF
bioactivity and enhanced the proliferation of OVA-spe-
cific CD8+ T cells in cell culture, we expressed the GM-
OVA fusion protein by DNA and adenoviral vectors in vivo
and determined ovalbumin-specific CD8+ T cell
responses. C57BL6 mice were either immunized by one or
two (week 0 and 5) DNA injections (-/D and D/D), a sin-
gle adenoviral vector injection (-/A) or a DNA prime
(week 0) and adenoviral vector boost (week 5) regimen
(D/A). The DNA and adenoviral vectors either encoded
the GM-OVA fusion protein or ovalbumin. One week
after the first or second immunization, OVA-specific
CD8+ T cell responses were determined using SIINFEKL/
H2-Kb tetramers. The functional activity of OVA-specific
CD8+ T cells was assessed by stimulation with the SIIN-
FEKL peptide followed by staining for interferon-γ and the
degranulation marker CD107a [32]. A single injection of
DNA encoding either OVA or GM-OVA did not result in
any detectable CD8+ T cell responses, while a single ade-
noviral vector immunization with either antigen resulted
in similar levels of tetramer-positive and IFN-γ/CD107a
double positive CD8+ T cells, with approximately 6% of
the total CD8+ T cells being specific for the SIINFEKL pep-
tide. After two injections of the OVA DNA vaccine, OVA-
Map and characterization of vaccine constructs Figure 1
Map and characterization of vaccine constructs. (A) Expression cassettes of the indicated vaccine constructs are shown. 
All open reading frames are under the control of the human cytomegalovirus immediate early promoter (CMV) or its deriva-
tive (CMVtetO2). His6: C-terminal tag; L-GM: leader peptide of GM-CSF; m: murine; rh: rhesus monkey; " ": 
[Gly4Ser]3-linker. (B) Ovalbumin-specific Western Blot analysis of supernatants of 293T cells transiently transfected with plas-
mids containing the indicated expression cassettes. GFP: supernatant of cells transfected with a GFP expression plasmid. (C) 
GM-CSF dependent FDCP-1 proliferation. 293 cells were infected with adenoviral vectors containing the indicated expression 
cassettes and the GM-CSF levels in the supernatants were determined 24 h post infection. Serial dilutions of the supernatants 
were co-cultured with FDCP-1 cells for 2 days. Proliferation was measured by a MTT assay.BMC Immunology 2008, 9:13 http://www.biomedcentral.com/1471-2172/9/13
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specific CD8+ T cells became detectable constituting
approximately 0.4% of the CD8+ T cells. Two injections of
GM-OVA DNA did not result in detectable levels (> 0.1%)
of OVA-specific CD8+ T cells demonstrating reduced
CD8+ T cell responses for the GM-CSF ovalbumin fusion
protein. Significantly reduced CD8+ T cell responses
could also be observed for the GM-OVA fusion protein in
the DNA prime adenoviral vector boost immunization.
The mean percentage of tetramer positive CD8+ T-cells
decreased to 5,5% in the GM-OVA group compared to
13,8% of tetramer positive cells in animals immunized
with the vaccines only expressing ovalbumin (Fig 3A).
Results for the CD107a/IFN-γ staining paralleled the
results obtained with the tetramers (Fig. 3B). Priming with
the OVA DNA vaccine clearly enhanced CD8+ T cell
responses after the adenoviral vector immunization. In
contrast, CD8+ T cell responses after the adenoviral GM-
OVA boost were not enhanced by priming with GM-OVA
DNA (Fig 3A, B).
Humoral immune responses after immunization with gene-
based vaccines encoding the GM-CSF fusion protein
Since the fusion of GM-CSF to antigens has previously
been shown to enhance humoral immune responses to
the antigens, we also studied the effect of GM-OVA on
OVA-specific IgG1 and IgG2a antibody levels. Since a sin-
gle injection of the DNA and adenoviral vector vaccines
encoding either GM-OVA or OVA did not result in detect-
able antibody levels, only the results for two repeated
DNA injections and the DNA prime adenoviral vector
boost regimen are shown (Fig. 4). Strikingly, mice immu-
nized with GM-OVA by DNA or DNA plus adenoviral
boost did not produce any detectable levels of ovalbumin-
specific IgG2a antibodies. In contrast, immunization with
vaccines encoding only ovalbumin resulted in readily
detectable levels of antigen-specific IgG2a antibodies (Fig.
4B). Opposite effects were observed on ovalbumin-spe-
cific IgG1 antibody levels. These were significantly ele-
vated for the GM-OVA groups in comparison to the
groups immunized with the ovalbumin-expressing vac-
cines (Fig. 4A).
Stimulation of CD8+ T cell responses by vaccines 
coexpressing GM-CSF and ovalbumin
Suppression of CD8+ T cell responses by the GM-OVA
vaccines could be directly due to the bioactivity of GM-
CSF. If this were the case, the coexpression of GM-CSF and
ovalbumin from bicistronic expression cassettes should
also suppress CD8+ T cell responses. However, the oppo-
site effect was observed. Despite substantially lower oval-
bumin expression levels by the GM-DP-OVA vaccines
coexpressing GM-CSF and ovalbumin, DNA prime aden-
oviral vector boost immunization with GM-DP-OVA vac-
cines enhanced the percentage of SIINFEKL-specific CD8+
T cells compared to vaccines only expressing ovalbumin
(Fig 5, left column). This is in sharp contrast to the results
obtained after GM-OVA vaccination, which reduced the
percentage of tetramer positive CD8+ cells.
After immunization with the bicistronic vaccines more
than a quarter of all CD8+ cells were specific for ovalbu-
min. Given this extraordinarily high CD8+ T cell response,
Influence of GM-OVA on the generation of DC (A) and stimulation of OT-I specific T-cells (B) Figure 2
Influence of GM-OVA on the generation of DC (A) and stimulation of OT-I specific T-cells (B). A) BM-derived 
monocytes were cultured for 8 days in the presence of GM-OVA or recombinant GM-CSF (5 ng/ml each) and IL-4 (1 ng/ml). 
The CD11c+ cells were analysed for the expression of CD80, CD83, and CD86 surface markers before (left panel) and after 
addition of LPS (right panel). B) Splenocytes of TCR-transgenic OT-I mice were labelled with CFSE and incubated for 72 h in 
the presence of either ovalbumin, GM-OVA or OT-I peptide at the indicated final concentration. The addition of recombinant 
GM-CSF and ovalbumin as separate proteins did not induce proliferation (data not shown).BMC Immunology 2008, 9:13 http://www.biomedcentral.com/1471-2172/9/13
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the OVA-specific cells were further characterized function-
ally. Stimulation of the spleen cells of mice immunized
with the bicistronic vaccine with the SIINFEKL peptide
also resulted in more than 25% IFN-γ positive CD8+ cells.
Most of IFN-γ positive cells also displayed cytotoxic activ-
ity as indicated by costaining with the CD107a degranula-
tion marker (Fig 5, center column). In addition, the
coexpression of GM-CSF enhanced the percentage of IFN-
γ and interleukin 2 double-positive cells after peptide
stimulation, confirming the polyfunctional nature of the
CD8+ T cell responses induced by this potent immuniza-
tion regimen (Fig 5, right column). About 90% of all
tetramer-positive CD8 cells also showed the downregula-
tion of CD62L expression (Fig 6), which further indicates
an effector phenotype [33,34]. No qualitative differences
among the various immunization groups were detectable,
suggesting that GM-CSF only influences the quantity but
not the functional properties of the vaccine-induced
CD8+ T-cells.
CD8 T cell responses induced by vaccines encoding a 
biologically inactive GM-CSF ovalbumin fusion protein
In contrast to the GM-OVA vaccines, the coexpression of
GM-CSF and ovalbumin did not suppress CD8 T cell
responses. This indicates that the suppressive effects of
GM-OVA vaccines on the CD8 T cell responses are not
simply due to the biological activity of GM-CSF. To
exclude the possibility that immune responses were
affected by altered antigen expression levels, subcellular
localization, and/or stability of the fusion protein, mice
were also immunized with DNA and adenoviral vector
vaccines expressing a fusion protein of rhesus macaque
GM-CSF and ovalbumin. Although fully active on primate
cells, rhesus monkey GM-CSF was inactive in rodent cells
(Fig. 1C). In all parameters investigated, including
Tetramer analyses and intracellular staining for IFN-γ,
interleukin 2, and/or CD107a, the immune response
induced by the rhesus monkey GM-OVA vaccines did not
differ significantly from the response induced by the OVA
vaccines (Fig. 5 and 6).
Antibody responses induced by gene-based vaccines 
encoding bioinactive GM-CSF fusion protein or 
coexpressing GM-CSF and ovalbumin
The GM-OVA vaccines not only suppressed cellular
immune responses but also the antigen-specific IgG2a
antibody response (Fig 4B). Therefore, ovalbumin-spe-
cific antibody levels of the IgG1 and IgG2a subtype were
Prime-boost regimens of GM-OVA suppress OVA-specific CD8+ immune responses Figure 3
Prime-boost regimens of GM-OVA suppress OVA-specific CD8+ immune responses. Mice were immunized by one 
DNA (-/D), one adenoviral vector (-/A), two DNA (D/D), or a DNA prime adenoviral vector boost (D/A) injection. The DNA 
and adenoviral vector either encoded ovalbumin (OVA) or the GM-CSF-ovalbumin fusion protein (GM-OVA). One week after 
a single injection or the second injection the percentage of OT-I tetramer positive CD8+ cells (A) and IFN-γ and CD107a dou-
ble-positive CD8+ cells after stimulation with the OT-I peptide (B) were determined. All percentages are percent of CD8+ 
lymphocytes. Mean percentages with SEM of three independent experiments each with three animals per group are shown. 
Only statistically significant differences between immunization regimens expressing ovalbumin or GM-OVA in the one-way 
ANOVA test are indicated.BMC Immunology 2008, 9:13 http://www.biomedcentral.com/1471-2172/9/13
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also determined for the vaccines coexpressing GM-CSF
and ovalbumin or expressing the fusion protein of inac-
tive rhesus GM-CSF and ovalbumin. Vaccinations with
GM-OVA again suppressed OVA specific IgG2a antibody
responses in comparison to the vaccine expressing only
ovalbumin (Fig. 7). In contrast, the coexpression of GM-
CSF or the expression of the fusion proteins of rhesus
monkey GM-CSF and ovalbumin did not affect IgG1 and
IgG2a antibody levels in the DNA prime adenoviral vector
boost immunization regimen.
Induction of neutralizing antibodies to GM-CSF
Whereas CD8 T cell responses upon injection of the Ad-
OVA vaccine were significantly increased in DNA-OVA
primed mice, such a priming effect was not observed with
the DNA-GM-OVA prime and Ad-GM-OVA boost regimen
(Fig. 3), suggesting that immune responses elicited by
priming with DNA-GM-OVA might have suppressed the
secondary response. Since neutralizing antibodies to GM-
CSF have been observed previously after injection of
recombinant GM-CSF proteins [35,36], we analysed sera
from immunized mice for the presence of GM-CSF neu-
tralizing antibodies using the GM-CSF-dependent FDCP-
1 cells. While the sera of mice immunized with the GM-
OVA vaccines inhibited GM-CSF-dependent cell growth
down to a 1:100 dilution, no inhibitory activity on FDCP-
1 cells was observed for the sera of mice immunized with
vaccines coexpressing GM-CSF and OVA or expressing the
monkey GM-CSF ovalbumin fusion proteins (Fig. 8).
Consistently, autoantibodies binding to GM-CSF in an
ELISA were only detected in mice immunized with vac-
cines encoding the fusion proteins, but not in any of the
other vaccine groups (data not shown).
Influence of neutralizing antibodies to GM-CSF on immune 
responses and viral replication in a retroviral infection 
model
Since GM-CSF knock-out mice had an impaired CD8+ T
cell response after immunization with peptides [37], we
determined the relevance of neutralizing anti-GM-CSF
antibodies induced by immunization with the GM-OVA
vaccine, in the Friend-Virus (FV) infection model. Immu-
nological control of FV infection was shown to be depend-
ent on antibodies and CD4+, and CD8+ T-cell responses
[38,39]. To induce neutralizing GM-CSF antibodies mice
were primed with the DNA and boosted with the adeno-
viral vector vaccine, both expressing GM-OVA. As con-
trols, mice were immunized against OVA with vaccines
expressing either ovalbumin alone or GM-CSF and oval-
bumin from a bicistronic expression cassette. One week
after the adenoviral vector boost, neutralizing antibodies
were detected in all animals immunized with the GM-
GM-OVA alters the humoral immune response Figure 4
GM-OVA alters the humoral immune response. Mice were immunized as described in figure legend 3. Ovalbumin-spe-
cific IgG1 (A) and IgG2a (B) antibodies were determined by ELISA. Shown are the mean OD405 values with their SEM (n = 6) 
from the vaccinated animals. Immune sera were diluted 1 to 10 and 1 to 1000 for the determination of IgG2a and IgG1 anti-
body levels, respectively. Only statistically significant differences between immunization regimens expressing either ovalbumin 
or GM-OVA in the one-way ANOVA test are indicated.BMC Immunology 2008, 9:13 http://www.biomedcentral.com/1471-2172/9/13
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Coexpression of GM-CSF and ovalbumin enhances CD8+ immune responses Figure 5
Coexpression of GM-CSF and ovalbumin enhances CD8+ immune responses. Mice were immunized by the DNA 
prime adenoviral vector boost as described in figure legend 3 with the DNA and adenoviral vectors encoding the indicated 
expression cassettes (s. Fig. 1A). Representative dot blots for SIINFEKL tetramer staining (left column), CD107 and IFN-γ 
staining (center column) and IFN-γ and IL-2 staining (right column) of CD8+ lymphocytes obtained from individual mice immu-
nized with GM-DP-OVA (A) and OVA (B) are shown. Panel C gives the mean and SEM for the immunization groups indicated 
and the parameters analysed. Only statistically significant differences between the groups are indicated. Three independent 
immunization experiments with three animals per group were performed for the PBS, OVA, and GM-OVA groups, while one 
experiment was performed with a total of 6 mice for the GM-DP-OVA and the GMrh-OVA groups.BMC Immunology 2008, 9:13 http://www.biomedcentral.com/1471-2172/9/13
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OVA vaccines, but not in any of the other groups. The anti-
bodies remained detectable during the whole observation
period (data not shown). Induction of virus-specific
CD8+ and CD4+ T cell responses was determined by
MHC-I and MHC-II tetramer staining 11 days post chal-
lenge with FV. Similar levels of antigen-specific CD4+ and
CD8+ T cell responses were observed in all immunized
groups (Fig. 9A,C). In addition, FV loads in the blood and
the spleen were not affected notably by the type of vaccine
antigen (Fig. 9B,D). Thus vaccine-induced neutralizing
antibodies against GM-CSF neither influenced T cell
responses nor viral load after FV infection. Interestingly,
all immunized groups had significantly reduced numbers
of FV-specific CD8+-T-cells compared to the non-immu-
nized control animals (Fig. 9A), suggesting some interfer-
ence between vaccine-induced immune responses and
antiviral CD8+ T cell responses after FV infection.
Discussion
A side-by-side comparison of a DNA prime adenoviral
vector boost immunization regimen leading either to the
expression of a fusion protein of GM-CSF and the model
antigen or to the coexpression of GM-CSF and antigens as
two separate proteins revealed striking differences in the
induction of polyfunctional antigen-specific CD8+ T cell
responses and humoral immune responses. Immuniza-
GM-CSF does not influence the activation status of CD8+ lymphocytes Figure 6
GM-CSF does not influence the activation status of CD8+ lymphocytes. Mice were immunized as described in figure 
legend 5. The effector phenotype of the antigen-specific CD8+ cells was confirmed by costaining for CD8, SIINFEKL/H-2Kb, 
and CD62L. CD8 and Tetramer double positive cells were gated (A) and analysed for CD62L expression (B, D). D) Mean per-
centage and SEM of CD62L-low cells from the CD8 and Tetramer double positive cells from three mice per group are shown. 
Panel C gives a representative example of CD62L expression levels of the CD8+, but tetramer negative population.BMC Immunology 2008, 9:13 http://www.biomedcentral.com/1471-2172/9/13
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tion with gene-based vaccines encoding the bioactive GM-
CSF antigen fusion proteins suppressed CD8+ T cell
responses, while the coexpression of GM-CSF and anti-
gens stimulated these responses. Although the fusion pro-
teins enhanced the stimulation of antigen-specific CD8+
T cells in coculture experiments with antigen-presenting
cells, the induction of neutralizing antibodies to GM-CSF
probably counteracted any beneficial effect of the fusion
protein on the enhancement of antigen uptake or presen-
tation in vivo. the injection of recombinant GM-CSF pro-
teins or GM-CSF fusion proteins has been shown
previously to induce antibodies to GM-CSF in mice and
humans [29,35,36,40]. Differences in postranslational
modifications such as glycosylation patterns between the
recombinant proteins and the endogenously expressed
GM-CSF have been postulated to be responsible for this
loss of tolerance [35,40]. Since the GM-CSF expression
levels after infection with the bicistronic vector was the
same or even higher when compared to the GM-OVA
encoding vector, we can exclude that simple overexpres-
sion of the cytokine is a reason for the break of tolerance.
However, the induction of GM-CSF neutralizing antibod-
ies by genetic vaccines expressing GM-CSF antigen fusion
proteins in the vaccinees suggests an alternative mecha-
nism for this autoimmune response. B-cells with antigen
receptor specificities for GM-CSF might take up the GM-
CSF-antigen fusion protein and present antigen-derived
epitopes on MHC-II molecules. T-helper cells specific for
the antigen part of the GM-CSF fusion protein could then
stimulate these B-cells even in the absence of autoreactive
GM-CSF-specific T-helper cells. This would be consistent
with a previous hypothesis for the appearance of autore-
active antibodies [41] and with results from immuniza-
tion studies with other fusion proteins [42,43].
The consequences of neutralizing GM-CSF antibodies for
the host are not well defined. Reconstitution of white
blood cells after bone-marrow transplantation and
immune responses to a protein vaccine were not impaired
in the presence of GM-CSF autoantibodies [44]. Using the
FV infection model, we did not observe any negative
effects associated with GM-CSF autoantibodies either.
Consistently, no pathological alterations have been
reported to be associated with anti-GM-CSF antibodies in
cancer patients. However, GM-CSF knock out mice were
not able to generate CD8+ T cell responses after peptide
Coexpression of GM-CSF and ovalbumin does not bias the humoral immune response Figure 7
Coexpression of GM-CSF and ovalbumin does not bias the humoral immune response. Mice were immunized by 
DNA prime adenoviral vector boost injections as described in figure legend 5. Ovalbumin-specific IgG1 (A) and IgG2a (B) anti-
bodies were determined by ELISA. Shown are the mean OD405 values with their SEM (n = 6) from the vaccinated animals. 
Immune sera were diluted 1 to 10 and 1 to 1000 for determination of IgG2a and IgG1 antibody levels, respectively. Only statis-
tically significant differences between immunization regimens expressing either ovalbumin or GM-OVA in the one-way ANOVA 
test are indicated.BMC Immunology 2008, 9:13 http://www.biomedcentral.com/1471-2172/9/13
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immunization and IgG2a antibody production was also
reported to be delayed after protein immunization [37].
In the present study, induction of GM-CSF neutralizing
antibodies coincided with suppression of CD8+ T cell
responses induced by a DNA prime adenoviral vector
boost regimen. Lack of suppression of CD8+ T cell
responses after a single immunization with the same DNA
or adenoviral vector vaccine further supports a causal rela-
tionship between GM-CSF antibodies and suppression of
CD8+ T cell responses, since in these immunization
experiments GM-CSF neutralizing antibodies are absent at
the time point of T cell priming. Depending on the precise
immunostimulatory pathways employed by a vaccine or
pathogen, the requirement for GM-CSF might differ sig-
nificantly, providing an explanation for the different
observations made in the mouse models. Although there
is no direct evidence of clinical complications so far, pos-
sible long-term consequences of the anti-GM-CSF
responses, such as involvement in pulmonary alveolar
proteinosis (PAP) [45,46], are difficult to exclude. Given
the loss of tolerance by other fusion proteins [42,43] and
the immunogenicity of genetic vaccines, a more general
note of caution regarding the use of genetic vaccines
encoding fusion proteins between host proteins and het-
erologous antigens might even be justified.
In contrast to immunization with genetic vaccines encod-
ing the GM-CSF-antigen fusion proteins, which strongly
suppressed IgG2a antibody responses, the coexpression of
GM-CSF and antigens in the DNA prime adenoviral vector
boost regimen did not modulate IgG1 and IgG2a anti-
body responses notably. This was unexpected, since
repeated immunizations with adenoviral vectors coex-
pressing GM-CSF and the amyloid-beta protein by the
intranasal route resulted in a Th2-type immune response
[47]. In addition, the coexpression of GM-CSF and anti-
gens in numerous DNA immunization studies increased
antibody responses [16,18,20-22]. Since the bicistronic
expression cassette in our study expresses lower amounts
of ovalbumin than the vaccine encoding ovalbumin only,
GM-CSF coexpression seems to compensate for the lower
antigen expression levels in the sense that in the presence
of GM-CSF a lower amount of antigen is needed to induce
comparable humoral immune responses than in its
absence. Previous studies also show that increased antigen
levels correlate with increased antibody titers, but do not
influence the dominant immunoglobulin subtype[48].
Thus, the difference in the IgG1/IgG2a ratio observed after
immunization with the genetic vaccine encoding the GM-
CSF-Ova fusion protein does not seem to be simply due to
GM-CSF receptor signalling, since this also occurs by the
coexpression of GM-CSF. However, immunization with
vaccines encoding rhesus monkey GM-CSF fused to oval-
bumin did not lead to a change in the IgG1/IgG2a ratio
either, although no differences were observed between the
expression levels of the two GM-CSF fusion proteins. This
indicates that the change in the antigen-specific IgG1/
IgG2a ratio observed after immunization with the fusion
protein depends on the GM-CSF bioactivity of the fusion
protein and the covalent linkage of GM-CSF with the anti-
gen.
The immunomodulatory properties of GM-CSF could also
differ substantially with the type of antigens, the route of
immunization, and/or the type of genetic vaccine used.
This also seems to apply to the effect of GM-CSF on CD8+
T cell responses. Coexpression of GM-CSF and antigens by
DNA vaccines was shown to stimulate CD8+ T cell
responses in some studies [17,49] but not in others
[19,50]. In the context of a DNA prime adenoviral vector
boost regimen, we observed that GM-CSF was a strong
stimulator of CD8+ T cell responses. Coexpression of GM-
CSF by the DNA and adenoviral vector vaccines enhanced
the percentage of CD8+ T cells specific for the immunodo-
minant epitope of the antigens from approximately 11%
to more than 25% as determined by tetramer staining and
intracellular IFN-γ staining. Although we can not com-
pletely rule out that the different antigen expression levels
influence the strength of immune response, it seems
unlike that lower antigen levels induce stronger CTL
responses. Rather, it has been reported that increased anti-
GM-OVA induces neutralizing antibodies against murine GM- CSF Figure 8
GM-OVA induces neutralizing antibodies against 
murine GM-CSF. Mice were immunized with the indicated 
DNA prime adenoviral vector boost regimens. One week 
after the adenoviral vector booster immunization, the GM-
CSF neutralizing activity was determined on the GM-CSF 
dependent FDCP-1 cell line stimulated with 2,5 ng murine 
GM-CSF/ml). Mouse sera were tested in a 1/20 (white bars) 
and a 1/100 (black bars) dilution. Medium without GM-CSF 
served as a negative control, whereas GM-CSF-containing 
medium without mouse serum was the positive control.BMC Immunology 2008, 9:13 http://www.biomedcentral.com/1471-2172/9/13
Page 11 of 15
(page number not for citation purposes)
gen expression levels obtained by codon-optimization or
enhanced promotor activities correlate with the better
induction of IFN-γ producing T-cells or cytotoxic T-cells
[48,51].
Coexpression of GM-CSF and ovalbumin by DNA prime
adenoviral vector boost immunizations led to a strong
CD8+ T cell response, with more than a quarter of all
CD8+ T cells being specific for a single immunodominant
peptide. Although the percentage of CD8+ T cell specific
for other antigens might well be lower than those
obtained in the present study with the ovalbumin model
antigens, the enhancement of CD8+ T cells responses by
GM-CSF is encouraging. The antigen-specific CD8+ T cells
induced in the presence of GM-CSF were not only numer-
ous, but also displayed markers of polyfunctional T cells
such as the coexpression of IFN-γ, IL-2, and the CD107a
degranulation marker. T cells that produce both IFN-γ and
IL-2 were recently proposed to be important in the control
of chronic viral infections, like CMV, EBV or in HIV LTNP
and might be indicative of long-lived memory T-cells [52].
Although the functional relevance of the CD8+ T cell
GM-CSF autoantibodies do not interfere with the control of FV infection Figure 9
GM-CSF autoantibodies do not interfere with the control of FV infection. GM-CSF autoantibodies were induced by 
DNA prime adenoviral vector boost immunization with the GM-OVA vaccines. As controls, groups of mice were immunized 
with the OVA or the GM-DP-OVA vaccines, or were mock vaccinated (PBS). Two weeks after the adenoviral vector booster 
immunization, mice were challenged with 3000 SFFU of FV. 11 days post challenge FV-specific immune responses were moni-
tored by MHC I (A) and MHC II (C) tetramer staining. Mean percentages and SEM (n = 6) of Tet+ CD8+ (A) and CD4+ (C) cells 
are shown. Splenocytes of an uninfected animal were used as negative control (naiv). The viral load in the blood was detected 
by AB34+ cells via flow cytometry (B). In addition the numbers of infectious centers per spleen were determined (D).BMC Immunology 2008, 9:13 http://www.biomedcentral.com/1471-2172/9/13
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response induced by DNA and adenoviral vector vaccines
coexpressing GM-CSF and antigens needs to be confirmed
in relevant tumor and infection models, GM-CSF should
be considered as a CD8+ T-cell adjuvant in DNA prime
adenoviral vector immunization regimens.
Conclusion
Genetic vaccines encoding fusion proteins between anti-
gens and a host protein led to the rapid induction of
autoantibodies. Therefore a more general note of caution
regarding the use of highly immunogenic viral vector vac-
cines encoding such fusion proteins seems to be justified.
In contrast, the coexpression of GM-CSF and antigens as
two separate proteins in DNA prime adenoviral vector
immunization regimens led to the enhanced induction of
polyfunctional CD8+ T-cells, further supporting a poten-
tial application of GM-CSF as an adjuvant not only for
DNA, but also for viral vector vaccines. Given the fact that
the DNA prime adenoviral vector boost regimen is pres-
ently one of the most efficient ways to induce CD8+ T cell
responses in mice, non-human primates and humans, the
enhancement of this response by GM-CSF is a striking
observation.
Methods
DNA and adenoviral vector vaccines
The DNA constructs used for the immunization studies
are all based on the expression plasmid pcDNA3.1 (Invit-
rogen, Karlsruhe, Germany) or pShuttle-CMV [53]. The
coding sequence of murine GM-CSF was amplified by RT-
PCR from RNA isolated from stimulated mouse spleno-
cytes and cloned into the pCR-2.1-TOPO vector (Invitro-
gen). All other plasmids were constructed via standard
cloning techniques including overlap extension PCR.
Transgene expression is driven in all constructs by the
immediate early promoter/enhancer region of human
cytomegalovirus. The open reading frame of the fusion
protein GM-OVA consisting of murine GM-CSF, a
[Gly4Ser]3 linker and OVA was cloned into the pcDNA3.1
vector. pOVA, also a pcDNA3.1 derivative, encodes oval-
bumin itself. Both proteins have a C-terminal HIS6-tag.
The plasmids pGMrh-OVA, pGM-DP-OVA, and pΔGM-
OVA are based on the pShuttle-CMV vector. The GMrh-
OVA fusion protein is equivalent to the mouse one with
the sequence of murine GM-CSF being replaced by the
rhesus monkey homologue. In the plasmid pGM-DP-
OVA, transgene expression is driven by a bidirectional ver-
sion of the CMV/TetO2 promoter [54]. In pΔGM-OVA the
coding sequence of ovalbumin is preceeded by the 17
amino acid long signal peptide of murine GM-CSF. All
DNA preparations for immunizations were carried out
with the Endofree Plamid Mega or Giga Kit (Qiagen,
Hilden, Germany).
All E1-deleted, replication-defective adenoviruses with the
corresponding expression cassettes (Ad-GM-OVA, Ad-
GM-DP-OVA, Ad-rhGM-OVA, Ad-ΔGM-OVA) were gener-
ated by the AdEasy-system [53]. The pShuttle plasmids
and pAdEasy1 were electroporated into BJ5183 bacteria as
previously described [54]. Correctly recombined plasmids
were transfected into 293 cells. Viral vectors growing out
were checked for transgene expression by Western Blot
analyses and GM-CSF bioactivity, if applicable. Vector
particles were purified by CsCl gradient centrifugation
and quantified by optical density measurements. In addi-
tion, the TCID50of the vectors were determined on 293
cells. The adenoviral vector preparations were also tested
for endotoxin levels with the LAL quantification assay
(Cambrex Bio Science, Verviers, Belgium), confirming
that the dose used for immunization of mice contained
less than 0,1 EU.
Cell culture media and reagents
HEK293 and 293T cells were cultured in DMEM contain-
ing 10% FCS and 1% penicillin/streptomycin. RPMI 1640
supplemented with 10% FCS, 2 mM L-Glutamine, 10 mM
HEPES, 50 μM  β-Mercaptoethanol and 1% antibiotic/
antimycotic (all Gibco, Karlsruhe, Germany) was used for
the lymphocyte cultures (R10-medium). Bone-marrow
cultures were grown in RPMI 1640, supplemented with
10% FCS, 1% penicillin/streptomycin, 4 mM L-
Glutamine, 1 mM sodium pyruvate and recombinant
mouse IL-4 (1 ng/ml) and GM-CSF (5 ng/ml) (Biomol,
Hamburg, Germany).
Expression and bioactivity of GM-OVA
293T cells were transfected using the calcium/phosphate
precipitation method. Supernatants were collected 48 h
after transfection and tested for protein expression by
Western Blot analysis. A combination of rabbit-α-OVA
(Chemicon International, LTD, Hampshire, UK) and
goat-α-rabbit-HRP (Sigma, Munich, Germany) antibodies
was used for detection. To confirm the bioactivity of GM-
OVA, it was purified from supernatants of transfected cells
by Ni-NTA-affinity chromatography as described by the
manufacturer (Qiagen, Hilden, Germany). The purified
protein migrated as a single band of the expected size in
Coomassie stained polyacrylamide gels. The GM-CSF-
dependent FDCP-1 cells were incubated with the purified
GM-OVA or supernatants from NIH 3T3 cells stably
expressing GM-CSF. The GM-CSF content of the superna-
tants had been determined by ELISA. After 48 h, GM-CSF-
dependent cell growth was monitored by MTT-assay as
described elsewhere [55,56]. Additionally, the ability to
generate DCs from bone marrow cultures was tested as
previously described [57]. Briefly, bone marrow derived
monocytes were cultured in the prescence of IL-4 and
recombinant GM-CSF or GM-OVA for 8 days, with or
without LPS maturation for 24 h. Their phenotype wasBMC Immunology 2008, 9:13 http://www.biomedcentral.com/1471-2172/9/13
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characterized by surface staining with the antibodies α-
CD11c-APC,  α-CD80-FITC,  α-CD86-FITC (all BD Bio-
science, Heidelberg, Germany) and α-CD83-PE (eBio-
science, San Diego, USA) in FACS analyses.
OT-I proliferation assay
Splenocytes of transgenic OT-I mice were incubated with
CFSE (3μM; Molecular Probes, Eugene, Oregon, USA) at a
density of 8 × 107 cells/ml for 6 min at room temperature
with gentle mixing. The labelling reaction was stopped by
adding one volume of FCS after which the cells were
washed twice with PBS. Thereafter, cells were plated into
96-well plates at a density of 1 × 106 cells/well and incu-
bated with different concentrations of either GM-OVA or
OVA (500 to 0,5 ng/ml) for 4 days. After washing the cells
twice with PBS containing 0,5% BSA and 1 mM sodium
azide (PBS/BSA/Azid), cell proliferation was measured in
FACS analysis. Cells, which were incubated with OT-I
peptide, were used as positive controls whereas non-stim-
ulated cells served as negative ones.
Animals and immunizations
6–8 week old female C57BL/6N mice were purchased
from Janvier (Le Genest-ST-Isle, France) and housed in
singly-ventilated cages in accordance with the national
law and institutional guidelines.
All vaccines were diluted in PBS and injected subcutane-
ously in both hind foot pads. For single dose experiments,
mice were immunized on day 1 with either 50 μg of DNA
(pOVA or pGM-OVA) or 5 × 109 adenoviral particles (Ad-
ΔGM-OVA resp. Ad-GM-OVA) corresponding to 2 × 108
50% tissue culture infectious doses (TCID50). After one
week, serum samples were collected and on day 8 animals
were sacrificed to analyze the CTL responses. In the prime-
boost experiments, all animals received an additional
DNA injection (pOVA or pGM-OVA) 5 weeks prior to the
above mentioned protocol. Serum samples were collected
28 days after the first and 7 days after the second immuni-
zation, whereas the T-cell assays were carried out 8 days
after the second immunization.
OVA specific antibody ELISA
Blood was taken retro-orbitally and serum was collected
after centrifugation for 5 min at 5.000 g in a table top cen-
trifuge. Ovalbumin protein (Sigma) was coated on 96-
well plates (MaxiSorb, Nunc, Wiesbaden, Germany) at a
final concentration of 5 μg/ml. After blocking with 5%
milk powder, serum samples were added at appropriate
dilutions and incubated for 1 h, followed by intensive
washing. Alkaline phosphatase-coupled antibodies
against mouse IgG1 or IgG2a antibodies (BD Bioscience)
were added and incubated for 1 h. The enzymatic reaction
was developed with the pNPP substrate (Sigma) for 30
min. Reaction was stopped by sodium hydroxide solution
(1 M) and the optical densities were measured at a wave-
length of 405 nm.
Tetramer and intracellular cytokine staining (ICS)
Splenocytes were collected at indicated time points. After
red blood cell lysis, 1 × 106 cells were plated in 96-well
round-bottom plates (Nunc) for each staining.
For the tetramer staining, cells were washed once and
incubated with 2 μl of SIINFEKL/H-2Kb-APC tetramers
(Sanquin, Amsterdam, NL) in total volume of 100 μl PBS/
BSA/Azid for 40 min at room temperature. After surface
staining with α-CD8-FITC, cells were incubated with 7-
amino-actinomycin D (7-AAD) for 5 min to exclude dead
cells from subsequent FACS analyses. In some experi-
ments,  α-CD62L-PE antibodies were included in the
tetramer analysis to characterize the CD8+ activation sta-
tus.
For ICS, samples were stimulated for 6 h in the presence
of 2 μM Monensin, which inhibits the cytokine secretion,
and 1 μl  α-CD107a-FITC, which is a marker for lym-
phocyte degranulation [32]. Cells were either stimulated
by α-CD3 and α-CD28 antibodies (2 μg/ml and 1 μg/ml,
respectively) or the OT-I/SIINFEKL peptide (2 μg/ml,
Genaxxon, Biberbach, Germany) and compared to non-
stimulated cultures. After stimulation, surface staining
was carried out with αCD8-PerCP or αCD4-FITC (BD Bio-
science). Cells were fixed in 2% paraformaldehyde, fol-
lowed by permeabilisation with 0,5% Saponin in PBS/
BSA/Azid buffer. Cytokines were detected with αIFN-γ-PE
and αIL-2-AlexaFluor647.
Friend virus challenge and virus detection
Mice were injected intravenously with 0.5 ml phosphate
buffered saline (PBS) containing 3,000 spleen focus-form-
ing units (SFFU) of the Friend virus complex (FV). The B-
tropic, polycythemia-inducing FV complex used in all
experiments was from uncloned virus stocks obtained
from 10% spleen cell homogenates as described previ-
ously [58].
For infectious center assays, single-cell suspensions from
infected mouse spleens were cocultivated with Mus dunnis
cells at 10-fold dilutions. Cultures were incubated for 5
days, fixed with ethanol, stained with F-MuLV envelope-
specific monoclonal antibody 720, and developed with
peroxidase-conjugated goat antimouse antibody and ami-
noethylcarbazol to detect foci. Tetramer analyses were
done by flow cytometry as described previously [59]. For
the quantification of Friend virus-infected blood cells, sin-
gle-cell suspensions of nucleated, live cells were analyzed
by flow cytometry. To detect Friend virus infection cells
were stained as described previously with tissue culture
supernatant containing Friend murine leukemia virus gly-BMC Immunology 2008, 9:13 http://www.biomedcentral.com/1471-2172/9/13
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cosylated Gag-specific monoclonal antibody 34 (AB34)
[60].
Statistical analysis
Results are expressed as the means ± standard errors of the
means (SEM). Statistical comparisons were performed by
one-way ANOVA test, followed by a Bonferroni post test
using the Prism 4.0, GraphPad Software. P < 0,05 was con-
sidered as statistically significant.
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